Clinical Trials Logo

Filter by:
NCT ID: NCT04121507 Completed - Lymphoma, B-Cell Clinical Trials

ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

Start date: June 24, 2019
Phase: Phase 2
Study type: Interventional

A prospective Phase II clinical study to assess the efficacy and toxicity of high dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL) - ASTRAL

NCT ID: NCT04119843 Completed - Clinical trials for Severe Renal Impairment

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

SPARKLE
Start date: February 19, 2020
Phase: Phase 3
Study type: Interventional

The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.

NCT ID: NCT04119479 Completed - Stroke Clinical Trials

Interdisciplinary Platform for Rehabilitation Research and Innovative Care of Stroke Patients

ImPRoVe
Start date: June 27, 2017
Phase:
Study type: Observational

Observational study of functional recovery of stroke patients after discharge from rehabilitation

NCT ID: NCT04119362 Completed - Clinical trials for Pancreatic Adenocarcinoma

PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer

PARAGON
Start date: October 24, 2019
Phase:
Study type: Observational [Patient Registry]

Due to the generally poor prognosis, with no chance of long-term survival, health related quality of life is a very important objective in the treatment of patients with pancreatic cancer. The non-interventional, prospective, multicentre PARAGON study is desinged to evaluate the health-related quality of life in patients with metastatic pancreatic cancer, by analyzing the course of QoL throughout all applied therapy lines for patients with pancreatic adenocarcinoma, measured according to EORTC scoring manual and patient reported outcome.

NCT ID: NCT04117659 Completed - Clinical trials for Right-Sided Heart Failure

Phosphodiesterase-5-inhibitors for Right Heart Failure After Left Ventricular Assist Device Implantation

PIVAD
Start date: October 15, 2019
Phase: N/A
Study type: Interventional

Refractory right heart failure is common during the postoperative period after left ventricular assist device implantation. Oral phosphodiesterase-5 inhibitors are oft initiated in order to facilitate weaning from the intravenous inotropic substances. following this period many patients continue to receive the same medication in the long term, despite missing data on its therapeutic effect on right ventricular function.We hypothesise that beyond the acute postoperative period no additional benefit from the phosphodiesterase-5 inhibitors exists. The aim of the study is a detailed clinical and echocardiographic assessment of the right ventricular function after discontinuation of the medication in patients pretreated for at least one month after receiving left ventricular assist device.

NCT ID: NCT04117113 Completed - E. Coli Infection Clinical Trials

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

EXPECT-2
Start date: October 22, 2019
Phase:
Study type: Observational

The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This information will be used to support the development of a new vaccine to prevent Extraintestinal pathogenic Escherichia coli (ExPEC). E. coli bacteria are a leading cause of serious infections. Especially adults older than 60 years have a higher risk of developing such infections. To date, there is no vaccine available to prevent E. coli infections. To support the development of a vaccine, more information about E. coli infections is first needed. This information will be collected in the current study, such as: - Medical information such as medical history, diagnosis, duration of hospitalization - Treatment and outcome of the Extraintestinal pathogenic Escherichia coli (ExPEC) - Laboratory information

NCT ID: NCT04115852 Completed - Clinical trials for Binge-Eating Disorder

Interoceptive Nutritional Processing in Healthy Participants and Patients With Binge-Eating-Disorder

BAG-C
Start date: September 1, 2019
Phase:
Study type: Observational

Binge-Eating-Disorder (BED) is a common eating disorder characterized by recurring episodes of uncontrollable eating. The underlying neural mechanisms are largely unknown. However, dysfunctional hormonal satiety signaling as well as dysfunctional neural processing of food cues are discussed as possible casual factors in the development and maintenance of this disorder. Additional research is needed to specify the exact contribution of these observations and how they interact with each other. Accordingly, the current study plans to investigate metabolic gut-brain signaling to better understand the underlying causes of abnormal eating behavior. To this end, 25 healthy normal weight control participants as well as 25 patients with BED will be recruited. The responsivity of the hypothalamus (i.e., the core region of homeostatic control) and its interaction with the mesocorticolimbic reward system will be assessed by applying a single-blind, randomized, crossover design of intravenous infusion of glucose or NaCl. This approach allows the study of gut-brain signaling to the hypothalamus and the reward system by controlling for sensory aspects of food intake (sight, smell, and taste). The interaction between the hypothalamus and the mesocorticolimbic reward system will be investigated using an effective connectivity analysis. FMRI with high spatial resolution and with an optimized protocol for the investigation of the hypothalamus and the mesocorticolimbic reward system will be employed. A better understanding of the underlying psychobiological mechanisms of BED is a fundamental requirement for the development of improved prevention and treatment strategies

NCT ID: NCT04115475 Completed - Clinical trials for Spinal Muscular Atrophy

New Imaging Biomarkers for Muscular Diseases - Multispectral Optoacoustic Imaging in Spinal Muscular Atrophy

MSOT_SMA
Start date: November 7, 2019
Phase: N/A
Study type: Interventional

This study aims to refine the capability of MSOT to characterise muscle tissue and to determine non-invasive, quantitative biomarkers for the disease assessment in patients with spinal muscular atrophy (SMA) using Multispectral Optoacoustic Tomography (MSOT).

NCT ID: NCT04115293 Completed - Clinical trials for Myasthenia Gravis, Generalized

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

RAISE
Start date: September 17, 2019
Phase: Phase 3
Study type: Interventional

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

NCT ID: NCT04114539 Completed - Clinical trials for Tourette Syndrome in Adolescence

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

Start date: October 4, 2019
Phase: Phase 2
Study type: Interventional

This study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.